New Release: Alpha testing version has been released.

Fluocinolone Acetonide

D07C - Corticosteroids, combinations with antibiotics ATC D07CC02 Small molecule approved 1963 Parenteral Topical

JFDA label: Synalar-N ointment

Mechanism of Action

Agonist of Glucocorticoid receptor — Glucocorticoid receptor agonist

TargetActionGene / class
Glucocorticoid receptor efficacy AGONIST NR3C1

Indications

Approved

  • Dermatitis, Atopic — atopic eczema
  • Dermatitis, Seborrheic — seborrheic dermatitis
  • Eye Diseases — eye inflammation
  • Hemorrhoids — hemorrhoid
  • Infections — infectious disease
  • Macular Edema — macular retinal edema
  • Melanosis — freckles
  • Psoriasis — psoriasis
  • Skin Diseases — skin disease
  • Uveitis — uveitis

Off-label

  • Macular Degeneration
  • Retinal Diseases
  • Uveitis, Anterior
  • Uveitis, Intermediate
  • Uveitis, Posterior

Contraindications

Source: openFDA

  • Ocular or Periocular Infections (4.1) Glaucoma (4.2) Hypersensitivity (4.3) 4.1 Ocular or Periocular Infections ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases. 4.2 Glaucoma ILUVIEN is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8. 4.3 Hypersensitivity ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product. Absolute

Dosing

Source: openFDA

For ophthalmic intravitreal injection. (2.1) The intravitreal injection procedure should be carried out under aseptic conditions. (2.2) Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. (2.2) 2.1 General Dosing Information For ophthalmic intravitreal injection. The initial prescription and renewal of the medication order of ILUVIEN should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. 2.2 Administration The intravitreal injection procedure should be carried out under aseptic conditions, which include use of sterile gloves, a sterile drape, a sterile caliper, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection. The injection procedure for ILUVIEN is as follows: The exterior of the tray should not be considered sterile. An assistant (non-sterile) should remove the tray from the carton and examine the tray and lid for damage. If damaged, do not use unit. If acceptable, the assistant should peel the lid from the tray without touching the interior surface. Visually check through the viewing window of the preloaded applicator to ensure that there is a drug implant inside. Remove the applicator from the tray with sterile gloved hands touching only the sterile interior tray surface and applicator. Prior to injection, the applicator tip must be kept above the horizontal plane to ensure that the implant is properly positioned within the applicator. To reduce the amount of air administered with the implant, the administration procedure requires two steps. Before inserting the needle into the eye, remove the protective cap then gently push the applicator button down and slide it to the first stop (at the curved black marks alongside the button track). At the first stop, release the button and it should move to the UP position. If the button does not rise to the UP position, do not proceed with this unit. Optimal placement of the implant is inferior to the optic disc and posterior to the equator of the eye. Measure 4 millimeters inferotemporal from the limbus with the aid of calipers for point of entry into the sclera. Inspect the tip of the needle to ensure it is not bent. Gently displace the conjunctiva so that after withdrawing the needle, the conjunctival and scleral needle entry sites will not align. Care should be taken to avoid contact between the needle and the lid margin or lashes. Insert the needle through the conjunctiva and sclera. To release the implant, while the button is in the UP position, advance the button by sliding it forward to the end of the button track and remove the needle. Note: Ensure that the button reaches the end of the track before removing the needle. Remove the lid speculum and perform indirect ophthalmoscopy to verify placement of the implant, adequate central retinal artery perfusion and absence of any other complications. Following the injection, patients should be monitored for change in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report without delay any symptoms suggestive of endophthalmitis.

Warnings & Precautions

Source: openFDA

Warnings & Precautions

Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. (5.1) Intraocular Pressure (IOP) Increase : Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity, and fields of vision. (5.2) Cataracts : Use of corticosteroids may result in posterior subcapsular cataract formation. (5.3) Delayed Healing : The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation. (5.4) Corneal and Scleral Melting : In those diseases causing thinning of the cornea or sclera, ophthalmic corticosteroids may lead to perforation of the globe. (5.5) Bacterial Infections : Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. (5.6) Viral Infections : Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). (5.7) Fungal Infections : Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. (5.8) Implant Migration : The implant may migrate into the anterior chamber if the posterior lens capsule is not intact. (5.9)

Intravitreal Injection-related Effects Intravitreal injections, includ

Intravitreal Injection-related Effects Intravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. For patients with non-infectious uveitis affecting the posterior segment, hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection [see Patient Counseling Information (17) ] . Patients may experience temporary blurred vision after injection of the implant.

Intraocular Pressure (IOP) Increase Prolonged use of corticosteroids m

Intraocular Pressure (IOP) Increase Prolonged use of corticosteroids may result in the development of glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be routinely monitored during the course of the treatment.

Cataracts The use of corticosteroids may result in posterior subcapsul

Cataracts The use of corticosteroids may result in posterior subcapsular cataract formation.

Delayed Corneal Wound Healing The use of corticosteroids after catarac

Delayed Corneal Wound Healing The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Corneal and Scleral Melting Various ocular diseases and long-term use

Corneal and Scleral Melting Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of ophthalmic corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation of the globe.

Bacterial Infections Prolonged use of corticosteroids may suppress the

Bacterial Infections Prolonged use of corticosteroids may suppress the host immune response and thus increase the hazard of secondary ocular infections. Acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.

Viral Infections Use of ocular corticosteroids may prolong the course

Viral Infections Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.

Fungal Infections Fungal infections of the cornea are particularly pro

Fungal Infections Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.

Risk of Implant Migration Patients in whom the posterior capsule of th

Risk of Implant Migration Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

Chemistry & Properties

2D structure
FormulaC24H30F2O6
Molecular weight452.49 g/mol
IUPAC name(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
CAS67-73-2
PubChem CID6215
InChIKeyFEBLZLNTKCEFIT-VSXGLTOVSA-N
logP2.37 (XLogP 2.5)
Polar surface area93.06 Ų
H-bond acceptors / donors6 / 2
Drug-likeness (QED)0.67
Lipinski violations0
SMILESCC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrantYes

Enzyme interactions

EnzymeRoleDetail
CYP2B6Inhibitor
CYP2C8Inhibitor
CYP3A4Inhibitor
CYP3A4Substrate

Receptor binding (top 1)

TargetActionAffinity
Glucocorticoid receptor (NR3C1) Agonist pIC50 8.5

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Registered Products (16)

BrandForm / strengthPackAgentCitizen (JOD)
proctolar center oint. Ointment 2 %, 0.01 %, 0.25 %, 5 % 15 g tube pack varies Arab Center for Pharmaceuticals & Chemicals 1.350
Petralar Cream Cream 0.025 % w/w 15 g tube MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 1.500
Petralar Ointment Ointment 0.025 % 15 g tube MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 1.500
petralar N cream. Cream 0.25 mg/g, 3.50 mg/g 15 g tube MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 1.500
petralar N oint. Ointment 0.25 mg/g, 3.50 mg/g 15 g tube MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 1.500
Proctoheal New Cream 0.1 mg/g, 20 mg/g 15 g tube Dar Al Dawa Development and Investment Co Ltd/Jordan 1.720
proctolar center supp Suppository 0.1 mg, 5 mg, 100 mg, 40 mg 10 MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 2.030
Proctoheal New Supp Suppository 0.1 mg, 40 mg 10 Dar Al Dawa Development and Investment Co Ltd/Jordan 2.180
proctolar center oint. Ointment 2 %, 0.01 %, 0.25 %, 5 % 30 g tube pack varies Arab Center for Pharmaceuticals & Chemicals 2.470
Petralar Forte Cream Cream 0.25 % w/w 15 g tube MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 2.500
Petralar Forte Ointment Ointment 0.25 % w/w 15 g tube MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 2.500
Procto synalar oint Ointment 20 mg, 0.1 mg 15 g tube Nabulsi Drug Store 2.790
Synalar-N cream Cream 0.025 %, 0.5 % 15 g tube Nabulsi Drug Store 3.200
Synalar-N ointment Ointment 0.025 %, 0.5 % 15 g tube Nabulsi Drug Store 3.200
Procto synalar supp Suppository 40 mg, 0.11 mg 10 Nabulsi Drug Store 4.110
Triderma Cream 0.05 %, 4 %, 0.01 % 30 g tube PELLA PHARMACEUTICALS CO.LTD/JORDAN 11.510